acetyl triethylammonium chloride | 29368-49-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: acetyl triethylammonium chloride
• 英文别名: Acetyl(triethyl)azanium;chloride
• CAS: 29368-49-8
• 化学式: C₈H₁₈NO*Cl
• 分子量: 179.69
• InChiKey: MVWTWNIDSWLQQC-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.59
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  三乙胺 、 乙酰氯 以 氘代氯仿 为溶剂， 反应 2.0h， 生成 acetyl triethylammonium chloride
  参考文献：
  名称：

  使用微流控带状线核磁共振装置在线监测苯甲醇的胺催化乙酰化反应

  摘要：

  我们通过核磁共振 (NMR) 监测 1.5 秒到几分钟的反应，对 N,N-二异丙基乙胺 (DIPEA) 存在下的苯甲醇乙酰化进行了深入研究。我们对 NMR 设置进行了调整，使其与微反应器技术兼容，将商用 NMR 探针的典型样品体积 (500 μL) 缩小到检测体积为 150 nL 的微流体带状线设置。获得在线光谱以监测动力学并揭示该工业相关反应的反应机理。该实验与传统的 2D NMR 测量相结合来鉴定反应产物。此外，我们用三乙胺和吡啶代替DIPEA来验证不同胺催化剂的反应机理。在所有三个乙酰化反应中，我们发现乙酰铵离子是关键中间体。当存在叔胺时，在反应的最初几分钟内观察到乙烯酮的形成。吡啶催化的反应通过不同的机制进行。

  DOI：

  10.1021/jacs.9b00039

文献信息

• Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
  申请人：Vical Incorporated.

  公开号：US20040157789A1

  公开（公告）日：2004-08-12

  This invention relates generally to the freeze-drying of formulations comprising a polynucleotide, a block copolymer and a cationic surfactant. In the presence of a cryoprotectant or bulking agent, a formulation can be freeze-dried, whereby upon reconstitution of the dried formulation, the microparticles maintain their optimal size and aggregation or fusion is avoided.

  本发明一般涉及由多核苷酸、嵌段共聚物和阳离子表面活性剂组成的制剂的冷冻干燥。在有低温保护剂或膨松剂存在的情况下，制剂可被冷冻干燥，从而在对干燥的制剂进行复溶时，微颗粒可保持其最佳尺寸，避免聚集或融合。
• METHOD FOR FREEZE-DRYING NUCLEIC ACID/BLOCK COPOLYMER/CATIONIC SURFACTANT COMPLEXES
  申请人：VICAL INCORPORATED

  公开号：EP1578193A2

  公开（公告）日：2005-09-28
• METHOD FOR PRODUCING STERILE POLYNUCLEOTIDE BASED MEDICAMENTS
  申请人：VICAL INCORPORATED

  公开号：EP1581201A1

  公开（公告）日：2005-10-05
• Method for producing sterile polynucleotide based medicaments
  申请人：Vical Incorporated.

  公开号：US20040162256A1

  公开（公告）日：2004-08-19

  The present invention relates to a novel method for producing formulations comprising a polynucleotide, block copolymer and cationic surfactant. The formulations produced by the current method are suitable for use in polynucleotide based medicaments. A suitable method of production disclosed herein additionally comprises cold filtering a mixture of a polynucleotide, block copolymer and cationic surfactant, thereby sterilizing the formulation. The method of the present invention also eliminates the need for thermal cycling of the formulation, thereby reducing the time and expense required to produce large quantities of a formulation during commercial manufacturing. The present invention also relates to novel cationic lipids.
• Methods for producing block copolymer/amphiphilic particles
  申请人：Geall Andrew

  公开号：US20060134221A1

  公开（公告）日：2006-06-22

  The invention relates to a method for manufacturing cell delivery particles, pharmaceutical component-particle dispersions, compositions comprising cell delivery particles and pharmaceutical compositions comprising pharmaceutical component-particle dispersions. The method comprises homogenization of mixtures comprising amphiphilic components and a block copolymer to form stable particles. The invention is also directed to cell delivery particles and pharmaceutical component-particle dispersions produced by the claimed methods and compositions comprising same. In certain embodiments, the cell delivery particles may further comprise co-lipids. The invention further relates to methods of generating an immune response, treating or preventing a disease or condition, or delivering a biologically active molecule to cells in vitro comprising administration of the pharmaceutical compositions described herein.